Across TCGA pan-cancer cohorts, GCM2 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of GCM2’s most consistent transcriptional readouts.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where GCM2 RNA is repressed in tumor relative to normal tissue. In most cancer types GCM2 is over-expressed in tumor, although a few such as UCEC and KIRP show the opposite, repressed pattern.
UCEC, BLCA, and KIRP are the cancer types where GCM2 tumor–normal differential expression is most reproducible.